Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvaro Gomez

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Autoimmunity Reviews|September 11, 2022
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literatureAlvaro Gomez, Ioannis Parodis
Rheumatology (Oxford, England)|January 12, 2024
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumabSandra Jägerback, Alvaro Gomez, Ioannis Parodis
Patient Related Outcome Measures|January 26, 2023
Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World EvidenceAlvaro Gomez, Yvonne Enman, Ioannis Parodis
Rheumatology International|March 7, 2024
Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional studyAlvaro Gomez, Ioannis Parodis, Christopher Sjöwall
Rheumatology (Oxford, England)|May 25, 2023
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trialsAlvaro Gomez, Sandra Jägerback, Christopher Sjöwall, et al.
Rheumatology (Oxford, England)|February 22, 2025
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumabAlvaro Gomez, Julius Lindblom, Ioannis Parodis, et al.
Chemical Communications (Cambridge, England)|October 28, 2021
Trends in non-isocyanate polyurethane (NIPU) developmentAlvaro Gomez-Lopez, Fermin Elizalde, Iñigo Calvo, et al.
ACS Applied Polymer Materials|December 19, 2022
Accelerating the Curing of Hybrid Poly(Hydroxy Urethane)-Epoxy Adhesives by the Thiol-Epoxy ChemistryAlvaro Gomez-Lopez, Bruno Grignard, Iñigo Calvo, et al.
Macromolecular Rapid Communications|November 27, 2020
Synergetic Effect of Dopamine and Alkoxysilanes in Sustainable Non-Isocyanate Polyurethane AdhesivesAlvaro Gomez-Lopez, Bruno Grignard, Iñigo Calvo, et al.
Rheumatology (Oxford, England)|June 4, 2019
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosusIoannis Parodis, Petter Johansson, Alvaro Gomez, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Autoimmunity Reviews|September 11, 2022
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literatureAlvaro Gomez, Ioannis Parodis
Rheumatology (Oxford, England)|January 12, 2024
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumabSandra Jägerback, Alvaro Gomez, Ioannis Parodis
Patient Related Outcome Measures|January 26, 2023
Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World EvidenceAlvaro Gomez, Yvonne Enman, Ioannis Parodis
Rheumatology International|March 7, 2024
Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional studyAlvaro Gomez, Ioannis Parodis, Christopher Sjöwall
Rheumatology (Oxford, England)|May 25, 2023
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trialsAlvaro Gomez, Sandra Jägerback, Christopher Sjöwall, et al.
Rheumatology (Oxford, England)|February 22, 2025
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumabAlvaro Gomez, Julius Lindblom, Ioannis Parodis, et al.
Chemical Communications (Cambridge, England)|October 28, 2021
Trends in non-isocyanate polyurethane (NIPU) developmentAlvaro Gomez-Lopez, Fermin Elizalde, Iñigo Calvo, et al.
ACS Applied Polymer Materials|December 19, 2022
Accelerating the Curing of Hybrid Poly(Hydroxy Urethane)-Epoxy Adhesives by the Thiol-Epoxy ChemistryAlvaro Gomez-Lopez, Bruno Grignard, Iñigo Calvo, et al.
Macromolecular Rapid Communications|November 27, 2020
Synergetic Effect of Dopamine and Alkoxysilanes in Sustainable Non-Isocyanate Polyurethane AdhesivesAlvaro Gomez-Lopez, Bruno Grignard, Iñigo Calvo, et al.
Rheumatology (Oxford, England)|June 4, 2019
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosusIoannis Parodis, Petter Johansson, Alvaro Gomez, et al.
Pageof 6